{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:47Z","timestamp":1786207367381,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In carefully selected patients, liver transplantation (LT) has provided encouraging outcomes for unresectable biliary tract cancers (BTC), including biphenotypic (cHCC-CC), perihilar (pCC), and intrahepatic cholangiocarcinoma (iCCA). This study aimed to characterize diagnostic discrepancies, recurrence patterns, and oncologic metrics in this unique LT population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with BTC receiving LT within a single academic transplant center were included (\n                      <jats:italic>n<\/jats:italic>\n                      = 98 from 2007 to 2025). Survival and recurrence outcomes were analyzed by tumor histotype using Kaplan\u2013Meier and log-rank tests. Univariate and multivariate Cox proportional hazards regression was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most common transplanted subtype was pCC (\n                      <jats:italic>n<\/jats:italic>\n                      = 54, 55.1%), followed by cHCC-CC (\n                      <jats:italic>n<\/jats:italic>\n                      = 28, 28.6%) and iCCA (\n                      <jats:italic>n<\/jats:italic>\n                      = 16, 16.3%). Pretransplant diagnoses frequently differed from final explant pathology in 26 patients (26.5%). Recurrence occurred in 40 (40.8%) patients with a median time to recurrence of 16 months (interquartile range 1\u2013160 months). Estimated 1-, 3-, and 5-year overall survival rates for the entire cohort were 88%, 68%, and 58%, respectively. On multivariate analysis, lymph node positivity (hazard ratio [3.27,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.010), iCCA subtype (HR 2.94,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.030), and explant tumor size (HR 1.22 per cm,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005) were independent predictors of recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is, to our knowledge, the largest single-center analysis of liver transplant recipients with BTC. Lymph node positivity, iCCA subtype, and tumor size are independent predictors of recurrence following LT for BTC. Despite the diagnostic challenges and high disease recurrence, LT is a promising option for unresectable BTC when no other surgical option exists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19975-6","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:22:57Z","timestamp":1781972577000},"page":"7870-7880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver Transplantation for Unresectable Biliary Tract Cancers: Largest Single-Center Analysis of Subtype-Specific Survival and Recurrence (2007\u20132025)"],"prefix":"10.1245","volume":"33","author":[{"given":"Sally","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Cullinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Vachharajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majella B. M.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"19975_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et al. Cholangiocarcinoma\u2014novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20:470\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"19975_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340.","journal-title":"Ann Oncol"},{"key":"19975_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","volume":"73","author":"SM Rushbrook","year":"2024","unstructured":"Rushbrook SM, Kendall TJ, Zen Y, Albazaz R, Manoharan P, Pereira SP, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2024;73:16\u201346.","journal-title":"Gut"},{"issue":"4","key":"19975_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.hpb.2021.08.940","volume":"24","author":"O Ahmed","year":"2022","unstructured":"Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MBM. Single-center experience of liver transplantation for perihilar cholangiocarcinoma. HPB (Oxford). 2022;24(4):461\u20139. https:\/\/doi.org\/10.1016\/j.hpb.2021.08.940.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"19975_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.32258","volume":"75","author":"G Sapisochin","year":"2022","unstructured":"Sapisochin G, Ivanics T, Heimbach J. Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time? Hepatology. 2022;75(2):455\u201372. https:\/\/doi.org\/10.1002\/hep.32258.","journal-title":"Hepatology"},{"key":"19975_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001449","author":"Y Dong","year":"2025","unstructured":"Dong Y, Li Z, Podrascanin V, Eaton JE, Ilyas SI, Gores GJ, Warner SG, Diwan TS, Nagorney DM, Heimbach JK, Smoot RL, Taner T, Starlinger PP. Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001449.","journal-title":"Hepatology"},{"issue":"2","key":"19975_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/13651820801993540","volume":"10","author":"RD Schulick","year":"2008","unstructured":"Schulick RD. Criteria of unresectability and the decision-making process. HPB (Oxford). 2008;10(2):122\u20135. https:\/\/doi.org\/10.1080\/13651820801993540.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"19975_CR8","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"19975_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"19975_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.841694","volume":"11","author":"D Sun","year":"2022","unstructured":"Sun D, Lv G, Dong J. Liver Transplantation for intrahepatic cholangiocarcinoma: what are new insights and what should we follow? Front Oncol. 2022;11:841694. https:\/\/doi.org\/10.3389\/fonc.2021.841694.","journal-title":"Front Oncol"},{"issue":"42","key":"19975_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000044942","volume":"104","author":"P Wei","year":"2025","unstructured":"Wei P, Ma D, Lo C, Luo Y, Gao J, Huang L, Zhu J, Li G, Zheng S, Li Z. Liver transplantation for intrahepatic cholangiocarcinoma: Insights from a National Registry Study in China. Medicine (Baltimore). 2025;104(42):e44942. https:\/\/doi.org\/10.1097\/MD.0000000000044942.","journal-title":"Medicine (Baltimore)"},{"key":"19975_CR12","doi-asserted-by":"publisher","first-page":"10630","DOI":"10.1038\/s41598-023-37896-2","volume":"13","author":"G Huang","year":"2023","unstructured":"Huang G, Song W, Zhang Y, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis. Sci Rep. 2023;13:10630. https:\/\/doi.org\/10.1038\/s41598-023-37896-2.","journal-title":"Sci Rep"},{"issue":"9","key":"19975_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cireng.2023.04.010","volume":"101","author":"V Garcia-Moreno","year":"2023","unstructured":"Garcia-Moreno V, Justo-Alonso I, Fernandez-Fernandez C, Rivas-Duarte C, Aranda-Romero B, Loinaz-Segurola C, Jimenez-Romero C, Caso-Maestro \u00d3. Long-term follow-up of liver transplantation in incidental intrahepatic cholangiocarcinoma and mixed hepatocellular-cholangiocarcinoma. Cir Esp (Engl Ed). 2023;101(9):624\u201331. https:\/\/doi.org\/10.1016\/j.cireng.2023.04.010.","journal-title":"Cir Esp (Engl Ed)"},{"issue":"12","key":"19975_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2025.102211","volume":"29","author":"R Anteby","year":"2025","unstructured":"Anteby R, Vierra BM, Shah SA. Liver transplant for intrahepatic cholangiocarcinoma: current evidence and clinical practice recommendations. J Gastrointest Surg. 2025;29(12):102211. https:\/\/doi.org\/10.1016\/j.gassur.2025.102211.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"19975_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/SLA.0000000000005641","volume":"276","author":"E Breuer","year":"2022","unstructured":"Breuer E, Mueller M, Doyle MB, Yang L, Darwish Murad S, Anwar IJ, Merani S, Limkemann A, Jeddou H, Kim SC, L\u00f3pez-L\u00f3pez V, Nassar A, Hoogwater FJH, Vibert E, De Oliveira ML, Cherqui D, Porte RJ, Magliocca JF, Fischer L, Fondevila C, Zieniewicz K, Ram\u00edrez P, Foley DP, Boudjema K, Schenk AD, Langnas AN, Knechtle S, Polak WG, Taner CB, Chapman WC, Rosen CB, Gores GJ, Dutkowski P, Heimbach JK, Clavien PA. Liver Transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an International Benchmark Study. Ann Surg. 2022;276(5):846\u201353. https:\/\/doi.org\/10.1097\/SLA.0000000000005641.","journal-title":"Ann Surg"},{"key":"19975_CR16","doi-asserted-by":"publisher","unstructured":"Sapisochin G, Facciuto M, Rubbia\u2010Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez\u2010Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PTW, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, on behalf of the iCCA International Consortium. Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178\u20131188. https:\/\/doi.org\/10.1002\/hep.28744.","DOI":"10.1002\/hep.28744"},{"issue":"4","key":"19975_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jamcollsurg.2020.11.017","volume":"232","author":"LA Dageforde","year":"2021","unstructured":"Dageforde LA, Vachharajani N, Tabrizian P, Agopian V, Halazun K, Maynard E, Croome K, Nagorney D, Hong JC, Lee D, Ferrone C, Baker E, Jarnagin W, Hemming A, Schnickel G, Kimura S, Busuttil R, Lindemann J, Florman S, Holzner ML, Srouji R, Najjar M, Yohanathan L, Cheng J, Amin H, Rickert CA, Yang JD, Kim J, Pasko J, Chapman WC, Majella Doyle MB. Multi-center analysis of liver transplantation for combined hepatocellular carcinoma-cholangiocarcinoma liver tumors. J Am Coll Surg. 2021;232(4):361\u201371. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2020.11.017.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"19975_CR18","doi-asserted-by":"publisher","first-page":"zraf034","DOI":"10.1093\/bjsopen\/zraf034","volume":"9","author":"BVM Dasari","year":"2025","unstructured":"Dasari BVM, Line PD, Sapisochin G, Hibi T, Bhangui P, Halazun KJ, Shetty S, Shah T, Magyar CTJ, Donnelly C, Chatterjee D. Liver transplantation as a treatment for cancer: comprehensive review. BJS Open. 2025;9(3):zraf034. https:\/\/doi.org\/10.1093\/bjsopen\/zraf034.","journal-title":"BJS Open"},{"key":"19975_CR19","doi-asserted-by":"publisher","unstructured":"Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88-98.e3; quiz e14. https:\/\/doi.org\/10.1053\/j.gastro.2012.04.008.","DOI":"10.1053\/j.gastro.2012.04.008"},{"key":"19975_CR20","doi-asserted-by":"publisher","unstructured":"Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451\u20138; discussion 458\u201361. https:\/\/doi.org\/10.1097\/01.sla.0000179678.13285.fa.","DOI":"10.1097\/01.sla.0000179678.13285.fa"},{"key":"19975_CR21","unstructured":"Organ Procurement and Transplantation Network (OPTN). Guidance to Liver Transplant Programs and the NationalLiver Review Board for Adult MELD Exceptions for Transplant Oncology. Published July 1, 2025. Accessed November 1,2025. https:\/\/optn.transplant.hrsa.gov\/professionals\/by-topic\/guidance\/liver-review-board-guidance\/"},{"key":"19975_CR22","doi-asserted-by":"publisher","first-page":"13641","DOI":"10.3389\/ti.2024.13641","volume":"37","author":"M Maspero","year":"2024","unstructured":"Maspero M, Sposito C, Bongini MA, Cascella T, Flores M, Maccauro M, Chiesa C, Niger M, Pietrantonio F, Leoncini G, Bellia V, Bhoori S, Mazzaferro V. Liver transplantation for intrahepatic cholangiocarcinoma after chemotherapy and radioembolization: an intention-to-treat study. Transpl Int. 2024;37:13641. https:\/\/doi.org\/10.3389\/ti.2024.13641.","journal-title":"Transpl Int"},{"issue":"14","key":"19975_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"15","key":"19975_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3748\/wjg.v28.i15.1574","volume":"28","author":"ZB Yuan","year":"2022","unstructured":"Yuan ZB, Fang HB, Feng QK, Li T, Li J. Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: a retrospective study. World J Gastroenterol. 2022;28(15):1574\u201387. https:\/\/doi.org\/10.3748\/wjg.v28.i15.1574.","journal-title":"World J Gastroenterol"},{"key":"19975_CR25","doi-asserted-by":"publisher","first-page":"11274","DOI":"10.1002\/cam4.5836","volume":"12","author":"SJ Yoon","year":"2023","unstructured":"Yoon SJ, Hong SS, Gwon MJ, et al. Effect of local treatment in patients with oligo-recurrence after surgery of distal bile duct cancer: a bi-institutional study. Cancer Med. 2023;12:11274\u201383. https:\/\/doi.org\/10.1002\/cam4.5836.","journal-title":"Cancer Med"},{"issue":"6","key":"19975_CR26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1245\/s10434-020-08207-0","volume":"27","author":"K Morino","year":"2023","unstructured":"Morino K, Seo S, Yoh T, Fukumitsu K, Ishii T, Taura K, Morita S, Kaido T, Uemoto S. Proposed Defi nition forOligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratifi ed Analysis. Ann Surg Oncol. 2020;27(6):1908\u20131917. https:\/\/doi.org\/10.1245\/s10434-020-08207-0.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"19975_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1457496919832150","volume":"109","author":"V Sallinen","year":"2019","unstructured":"Sallinen V, Sir\u00e9n J, M\u00e4kisalo H, et al. Differences in prognostic factors and recurrence patterns after curative-intent resection of perihilar and distal cholangiocarcinomas. Scand J Surg. 2019;109(3):219\u201327. https:\/\/doi.org\/10.1177\/1457496919832150.","journal-title":"Scand J Surg"},{"key":"19975_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102649","volume":"122","author":"A Stenzinger","year":"2024","unstructured":"Stenzinger A, Vogel A, Lehmann U, Lamarca A, Hofman P, Terracciano L, et al. Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing. Cancer Treat Rev. 2024;122:102649.","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19975-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:49:15Z","timestamp":1786204155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19975"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19975-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B.M Doyle was a proctor for Intuitive and educator for Organox.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}